Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 27, 2026

Implantation of Engineered Tissue in the Rat Heart
07:59

Implantation of Engineered Tissue in the Rat Heart

Published on: June 24, 2009

10.7K

Engineered Heart Repair.

B Fujita1,2,3, W-H Zimmermann1,2

  • 1Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany.

Clinical Pharmacology and Therapeutics
|June 30, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Extracellular Vesicles Derived from Neural Progenitor Cells--a Preclinical Evaluation for Stroke Treatment in Mice.

Translational stroke research·2021
Same author

Network-driven discovery yields new insight into Shox2-dependent cardiac rhythm control.

Biochimica et biophysica acta. Gene regulatory mechanisms·2021
Same author

Extracellular Vesicles Derived from Neural Progenitor Cells--a Preclinical Evaluation for Stroke Treatment in Mice.

Translational stroke research·2020
Same author

Heart Transplantation in Systemic Sclerosis: New Impulses for Conventional Scleroderma Transplantation Regimen and Scleroderma Diagnostic Monitoring: 2 Case Reports.

Transplantation proceedings·2019
Same author

All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class.

Molecular psychiatry·2016
Same author

[Individualized stem cell therapy].

Herz·2014
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
See all related articles

Developing advanced heart failure therapies requires addressing cardiomyocyte loss. Tissue-engineered heart repair using stem cell-derived cardiomyocytes offers a promising solution for heart remuscularization, but faces pharmacological challenges for clinical translation.

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Research
  • Biomedical Engineering

Background:

  • Current heart failure treatments primarily manage symptoms by blocking neurohumoral overstimulation.
  • These therapies do not address the fundamental issue of cardiomyocyte loss in heart failure.
  • Regenerating lost cardiomyocytes is crucial for effective heart failure treatment.

Purpose of the Study:

  • To explore the pharmacological challenges associated with the clinical translation of tissue-engineered heart repair.
  • To focus on engineered heart muscle (EHM) as a potential therapeutic strategy for heart failure.
  • To advance the remuscularization of failing hearts through stem cell-based therapies.

Main Methods:

  • Review of current pharmacological strategies and their limitations in heart failure.

More Related Videos

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model
07:03

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Published on: March 18, 2019

7.8K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

Implantation of Engineered Tissue in the Rat Heart
07:59

Implantation of Engineered Tissue in the Rat Heart

Published on: June 24, 2009

10.7K
Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model
07:03

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Published on: March 18, 2019

7.8K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K
  • Discussion of stem cell-derived cardiomyocyte implantation techniques.
  • Analysis of challenges in translating engineered heart muscle (EHM) to clinical practice.

    • Main Results:

    • Identified significant pharmacological hurdles in the clinical application of tissue-engineered heart repair.
    • Highlighted the potential of engineered heart muscle (EHM) for cardiac regeneration.
    • Emphasized the need for further research into optimizing drug delivery and efficacy for EHM.

    Conclusions:

    • Tissue-engineered heart repair, particularly using engineered heart muscle (EHM), holds promise for treating heart failure by restoring cardiomyocyte populations.
    • Overcoming pharmacological challenges is critical for the successful clinical translation of these advanced regenerative therapies.
    • Further investigation into pharmacologic interventions is necessary to enhance the integration and function of implanted cardiomyocytes.